About: Edgar Faber

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Edgar Faber Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

researcher

Attributes	Values
rdf:type	Item
description	researcher (en) araştırmacı (tr) дослідник (uk) onderzoeker (nl) MUDr.,CSc., lékař, působící na lékařské fakultě Univerzity Palackého a na Hemato-onkologické klinice FN v Olomouci. (cs)
rdfs:label	Edgar Faber (cs) Edgar Faber (de) Edgar Faber (en) Edgar Faber (nl) Edgar Faber (sk)
skos:prefLabel	Edgar Faber (cs) Edgar Faber (de) Edgar Faber (en) Edgar Faber (nl) Edgar Faber (sk)
name	Edgar Faber (cs) Edgar Faber (de) Edgar Faber (en) Edgar Faber (nl) Edgar Faber (sk)
given name	wds:Q106984053-91E69F2B-5EBC-4C30-8949-8D9A2062A5A7
given name	Edgar
instance of	wds:Q106984053-1ED1681B-11EB-4767-9DA5-7921874A1C0B
NL CR AUT ID	wds:Q106984053-393BA7BA-6A53-497A-9480-2CA1D6F5A67C
instance of	Homo sapiens
NL CR AUT ID	xx0062699
vedidk ID	wds:Q106984053-648102A8-6C04-4F64-9E31-4FFD7122758A
vedidk ID	2556049
skos:altLabel	E. Faber (cs)
occupation	wds:Q106984053-87FCEA76-81B7-4A8B-869B-F08B589F591E
employer	wds:Q106984053-494D4E72-F977-42D1-8641-27980A9FDF42
VIAF ID	wds:Q106984053-737F5647-3BF9-419C-BC00-267BA58D64E1
family name	wds:Q106984053-E9F3674A-03F6-422D-9DE2-BF8F27A5AF5D
VIAF ID	http://viaf.org/viaf/60124471
occupation	researcher
employer	Palacký University Olomouc
VIAF ID	60124471
family name	Faber
ORCID iD	wds:Q106984053-7EA3B282-42EC-4400-97D1-9A8D5FCFCDA2
ORCID iD	https://orcid.org/0000-0002-3259-7791
ORCID iD	0000-0002-3259-7791
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q106984053
is author of	Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile Operational cures after interferon-alpha in patients with chronic myeloid leukemia in Central and Northern Moravia Saliva as a diagnostic medium Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting A European consensus report on blood cell identification: terminology utilized and morphological diagnosis concordance among 28 experts from 17 countries within the European LeukemiaNet network WP10, on behalf of the ELN Morphology Faculty Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha administration Isotope dilution direct injection mass spectrometry method for determination of four tyrosine kinase inhibitors in human plasma. Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000--a report from the population-based CAMELIA Registry Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation Detailed study of imatinib metabolization using high-resolution mass spectrometry Possible impact of MADCAM1 gene single nucleotide polymorphisms to the outcome of allogeneic hematopoietic stem cell transplantation Precursor T-lymphoblastic lymphoma as a secondary malignancy in a young patient after successful treatment of acute promyelocytic leukemia Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia Has the time come for induction and maintenance imatinib therapy in chronic myeloid leukemia? Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy in the rituximab era. Metabolite Profiling of the Plasma and Leukocytes of Chronic Myeloid Leukemia Patients. Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications Identification of e6a2 BCR-ABL fusion in a Philadelphia-positive CML with marked basophilia: implications for treatment strategy. Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy. Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia Allogeneic Stem Cell Transplantation for Non-Hodgkin Lymphoma: Data from National Czech Registry A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results. The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma. Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels. High serum carbohydrate antigen-125 (CA-125) level predicts poor outcome in patients with follicular lymphoma independently of the FLIPI score Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients Granulocyte transfusions collected after steroid priming for severe infections during neutropenia: A single center experience Salivary neutrophils level as an indicator of bone marrow engraftment Rituximab does not adversely affect the stem cell mobilization and engraftment after high-dose therapy and autologous transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation. Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma--results of a prospective multicentre controlled trial Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher pla ATM gene single nucleotide polymorphisms predict regimen-related gastrointestinal toxicity in patients allografted after reduced conditioning Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation. Ultrafast Online SPE-MS/MS Method for Quantification of 3 Tyrosine Kinase Inhibitors in Human Plasma. Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT Second Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation Successful childbirth in a patient with chronic myelogenous leukemia treated with imatinib mesylate during early pregnancy. Sources and pathways of spread of vancomycin-resistant enterococci in hemato-oncological patients Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma [Targeted treatment of chronic myeloid leukemia in the elderly patients] Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change. First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter wd:Q121963444 Novel sulphur-containing imatinib metabolites found by untargeted LC-HRMS analysis. Comparison of reduced conditionings combining fludarabine with melphalan or 3-day busulfan in patients allografted for myeloid neoplasms Interferon-alpha in chronic myeloid leukemia revisited: a long-term retrospective study in Central and Northern Moravia. Spontaneous splenic rupture in a patient with acute promyelocytic leukaemia during induction chemotherapy.
is author of	wds:Q35966977-A799B2A7-4C2F-4C04-88A6-0F4DB1D76EA8

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software